MINNEAPOLIS & DENVER--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today released new STOP AF (Sustained Treatment of Paroxysmal Atrial Fibrillation) clinical trial data showing the number of paroxysmal atrial fibrillation (AF) patients reporting AF symptoms declined by 80 percent after treatment with the Arctic Front® Cardiac CryoAblation Catheter System. Additionally, as reported in the quality-of-life questionnaire (SF-36) results, all patients randomized and treated with the Arctic Front Cardiac CryoAblation Catheter System reported significant improvements in physical and mental quality-of-life factors when compared to baseline measurements (P<0.001). These data were presented as a late breaking clinical trial at Heart Rhythm 2010, the Heart Rhythm Society’s 31st Annual Scientific Sessions. The CryoAblation System is commercially available for use in Europe; it is under investigational use in the United States.
